<DOC>
	<DOC>NCT01073644</DOC>
	<brief_summary>The primary purpose is to monitor the safety and tolerability and effectiveness of sunitinib malate in the treatment of patients with metastatic renal cell carcinoma and gastrointestinal stromal tumor among filipino patients in usual clinical practice setting.</brief_summary>
	<brief_title>Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients</brief_title>
	<detailed_description>Open label</detailed_description>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Age 18 years and above Diagnosed with metastatic renal cell carcinoma or gastrointestinal stromal tumor after imatinib treatment failure or intolerance Subjects with conditions that are contraindicated with sunitinib malate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>imatinib resistant or intolerant</keyword>
</DOC>